Evidence map›Paper›PMID 42356428›Full record

ArticlePharmaceuticals (Basel, Switzerland)2026

Composite CA15-3, LDH, and Albumin Index as a Predictor of Survival in HER2-Positive Metastatic Breast Cancer Treated with Trastuzumab Emtansine.

Nagihan Kolkıran, Atike Pınar Erdoğan, Mustafa Şahbazlar, Müge Kurul Yeniay, Sinan Ünal, Mehmet Sinan Akarca, Elif Atağ Akyürek, Özge Demirkıran, Bilgin Demir, Ferhat Ekinci

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Nagihan KolkıranDepartment of Medical Oncology, Faculty of Medicine, Manisa Celal Bayar University, Manisa 45030, Turkey.ORCID 0000-0001-9344-7212
Atike Pınar ErdoğanDepartment of Medical Oncology, Faculty of Medicine, Manisa Celal Bayar University, Manisa 45030, Turkey.
Mustafa ŞahbazlarDepartment of Medical Oncology, Faculty of Medicine, Manisa Celal Bayar University, Manisa 45030, Turkey.
Müge Kurul YeniayDepartment of Medical Oncology, Faculty of Medicine, İzmir Katip Çelebi University Atatürk Training and Research Hospital, İzmir 35360, Turkey.ORCID 0000-0002-6820-9738
Sinan ÜnalDepartment of Medical Oncology, Faculty of Medicine, İzmir Katip Çelebi University Atatürk Training and Research Hospital, İzmir 35360, Turkey.
Mehmet Sinan AkarcaDepartment of Medical Oncology, Faculty of Medicine, Dokuz Eylül University, İzmir 35340, Turkey.ORCID 0009-0001-5513-4351
Elif Atağ AkyürekDepartment of Medical Oncology, Faculty of Medicine, Dokuz Eylül University, İzmir 35340, Turkey.
Özge DemirkıranDepartment of Medical Oncology, Faculty of Medicine, Aydın Adnan Menderes University, Aydın 09100, Turkey.
Bilgin DemirDepartment of Medical Oncology, Faculty of Medicine, Aydın Adnan Menderes University, Aydın 09100, Turkey.ORCID 0000-0003-4380-9419
Ferhat EkinciDepartment of Medical Oncology, Faculty of Medicine, Manisa Celal Bayar University, Manisa 45030, Turkey.ORCID 0000-0002-9317-942X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

breast canceroverall survivalprognostic indextrastuzumab emtansine

Identifiers

PMID42356428
PMCPMC13305043

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.